Nearly 300 non-invasive diagnostic tests, Claims Roots Analysis

Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

• Type of Tumor Marker

• ctDNA
• cfDNA
• CTCs
• Exosomes
• Others

• Application

• Diagnosis / Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring

• Target Cancer Indication

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Bladder Cancer
• Melanoma
• Gastric Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

§  End Users

• Hospitals
• Research Institutes
• Others

§  Key Geographical Regions 

• North America
• Europe
• Asia-Pacific
• Rest of the World

The “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.”report features the following companies, which we identified to be key players in this domain:

§  Amoy Diagnostics

§  DiaCarta

§  HaploX Biotechnology

§  NeoGenomics

§  QIAGEN

§  Swift Biosciences

§  Sysmex Inostics

§  Thermo Fisher Scientific

To request for sample report - https://www.rootsanalysis.com/reports/279/request-sample.html

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Non-Invasive Cancer Screening and Diagnosis
 

5. Market Landscape

6. Company Profiles
 

7. Partnerships and Collaborations

8. Funding and Investment Analysis
 

9. Liquid Biopsy: Initiatives of Big Pharma Players
 

10. Key Acquisition Targets

11. Other Non-Invasive Cancer Diagnostics
 

12. Market Sizing and Opportunity Analysis
 

13. Survey Insights

14. Conclusion
 

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Other Recent Offerings:

1. Antibody Drug Conjugates Market (5th Edition), 2019-2030
2. Gene Therapy Market (3rd Edition), 2019 - 2030
3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Article source: https://article-realm.com/article/Sports-Recreation/15280-Nearly-300-non-invasive-diagnostic-tests-Claims-Roots-Analysis.html